Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 3,836

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Wen, Patrick Y., Macdonald, David R., Reardon, David A., Cloughesy, Timothy F., Sorensen, A. Gregory, Galanis, Evanthia, DeGroot, John, Wick, Wolfgang, Gilbert, Mark R., Lassman, Andrew B., Tsien, Christina, Mikkelsen, Tom, Wong, Eric T., Chamberlain, Marc C., Stupp, Roger, Lamborn, Kathleen R., Vogelbaum, Michael A., van den Bent, Martin J., Chang, Susan M. · 2010 · Journal of Clinical Oncology

Abstract

Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.26.3541

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 9

  1. 10.3171/jns.1996.84.2.0174 · doi:10.3171/jns.1996.84.2.0174
  2. 10.1016/j.surneu.2006.04.015 · doi:10.1016/j.surneu.2006.04.015
  3. 10.1002/ana.410170607 · doi:10.1002/ana.410170607
  4. 10.1148/radiology.204.3.9280269 · doi:10.1148/radiology.204.3.9280269
  5. Matheus MG, 2004, Am J Neuroradiol, 25, 1211
  6. Floeth FW, 2001, Am J Neuroradiol, 22, 1517
  7. 10.1023/A:1014571900854 · doi:10.1023/a:1014571900854
  8. 10.1016/j.crad.2006.09.012 · doi:10.1016/j.crad.2006.09.012
  9. 10.1055/s-0028-1083696 · doi:10.1055/s-0028-1083696

Cited by

See all 3,836

Metadata

Authors
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., Tsien, C., Mikkelsen, T., Wong, E. T., Chamberlain, M. C., Stupp, R., Lamborn, K. R., Vogelbaum, M. A., van den Bent, M. J., & Chang, S. M.
Venue
Journal of Clinical Oncology
Published
2010-04-10
Volume
28
Issue
11
Pages
1963-1972
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2162643152
Cited by
3,836
References
49
FWCI
69.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.